从保存的人肿瘤组织标本中分离浸润肿瘤淋巴细胞，用于下游鉴定。

Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization.

机构信息

Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Chiba 104-0045/277-8577, Japan; Becton, Dickinson and Company, Biosciences, Tokyo 107-0052, Japan.

Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo/Chiba 104-0045/277-8577, Japan.

出版信息

STAR Protoc. 2022 Sep 16;3(3):101557. doi: 10.1016/j.xpro.2022.101557. Epub 2022 Jul 18.

DOI:10.1016/j.xpro.2022.101557

PMID:35852944

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9304678/

Abstract

Immunophenotyping of tumor-infiltrating lymphocytes (TILs) by flow cytometry can predict clinical efficacy of immunotherapy. However, several obstacles need to be overcome for developing a flow cytometry assay starting from solid tumor specimens. Here, we show a detailed enzyme-based protocol to isolate TILs from human tumor tissues. The protocol was optimized to obtain enough viable TILs from a biopsy tissue specimen for flow cytometry-based TIL immunophenotyping. Additionally, tissue samples could be preserved for up to 72 h for subsequent characterization. For complete details on the use and execution of this protocol, please refer to Kumagai et al. (2020, 2022).

摘要

流式细胞术分析肿瘤浸润淋巴细胞（TILs）的免疫表型可预测免疫治疗的临床疗效。然而，要从实体瘤标本中开发流式细胞术检测方法，还需要克服几个障碍。本文展示了一种详细的基于酶的方法，用于从人类肿瘤组织中分离 TILs。该方案经过优化，可从活检组织标本中获得足够的活 TILs，用于基于流式细胞术的 TIL 免疫表型分析。此外，组织样本可保存长达 72 小时，以便后续进行特征分析。如需了解该方案的详细使用和实施步骤，请参考 Kumagai 等人（2020 年，2022 年）的文献。